Introduction
Neural stem/progenitor cells (NSCs) represent a heterogeneous population of multipotent cells able to self-renew and differentiate into astrocytes, neurons and oligodendrocytes [1] [2] . NSCs derived from different sources induce remarkable functional recovery in vivo after transplantation into laboratory animals with experimental neurological diseases. However, the extent to which transplanted animals recover from disease is unlikely to be attributable to the observed scarce differentiation of grafted cells [3] . Thus, it is anticipated that grafted NSCs exert at least some of their therapeutic benefits through a series of bystander effects that imply the release of tissue trophic and immune modulatory paracrine factors at the level of the microenvironment [4] [5] [6] [3] . In some pathological conditions (e.g. spinal cord injury), the CNS environment is substantially altered, often characterized by an increase in the extracellular concentration of glutamate, the major responsible of excitotoxicity and neurodegeneration following injuries [7] . The effects of glutamate are mediated both by ionotropic receptors/channels (iGluRs) [8] and by metabotropic receptors (mGluRs) [9] . The activation of group I mGluRs (composed of mGluR1 and mGluR5) via the administration of specific agonists induces the proliferation of rodent embryonic stem cells and NSCs, as well as human NSCs, both in vitro and in vivo [10] [11] [12] [13] .
Objective
To analyze the expression and function of mGluRs in spinal cord derived-NSCs; To demonstrate the prominent role of mGluR1 and mGluR5 in regulating the increase of intracellular Ca 2+ in spinal cord derived-NSCs; To demonstrate that Group I metabotropic glutamate receptor signaling regulates the release of BDNF and LIF by spinal cord derived-NSCs. . Data are expressed as mean (n≥3) ± s.e.m. and were analyzed with one-way-ANOVA and Bonferroni post-test correction for multiple comparisons. In (G) the difference is vs DHPG if not specified. * p≤0.05; ** or ## p≤0.005; *** p≤0.0005; **** p≤0.0001.
Results & Discussion mGluRs expression and functional characterization in SC-NSCs
We isolated stably expandable NSCs from the spinal cords of adult mice and compared their proliferation and differentiation properties with those of previously characterized subventricular zone (SVZ)-derived NSCs [14] (Fig. 1A and Suppl. Fig. 1 ). Previous work demonstrated that SVZ-NSCs express the transcripts of all mGluRs subtypes with the exception of mGluR2 and mGluR6 [15] . By means of a semiquantitative RT-PCR, here we observed that SC-NSCs expressed all the transcripts, with the exception of mGluR8. We also detected two different isoforms of mGluR1 in SC-NSCs, with only one transcript for mGluR5 (Fig. 1B) . We confirmed the expression of mGluR1 and mGluR5 by immunocytochemistry (Fig. 1C) . We then performed live Ca 2+ imaging to assess the functionality of the identified glutamate receptors on SC-NSCs (Suppl. Fig. 2 ). Treatment with 50 μM glutamate alone activated significant intracellular Ca 2+ transients (Fig. 1D) . We then observed a partial reduction of [Ca 2+ ]i transients when glutamate was administered in the presence of the specific NMDA receptor antagonist AP5 or the specific AMPA receptor antagonist CNQX (Fig. 1D) . Quantification of active cells did not show any significant difference, vs. glutamate alone (Fig. 1E) . Importantly, we observed significant decrease of both the [Ca 2+ ]i transients (Fig. 1D) as well as the proportion of responding cells (Fig. 1E ) when glutamate was administered in the presence of the selective non-competitive antagonist of mGluR5 MPEP, or the selective competitive inhibitor of mGluR1 LY367385. Treatment with the specific agonist of group I metabotropic receptors DHPG also led to a significant increase of [Ca 2+ ]i, (Fig. 1D and E) . Instead, treatment with DHPG in the presence of either MPEP or LY367385 resulted into a dampened average [Ca 2+ ]i transients (not shown), and decreased number of responding cells (Fig. 1E) . Therefore, glutamate induced an increase in [Ca 2+ ]i within SC-NSCs and its action was highly dependent on the activity of group I mGluRs.
Effects of signaling via Group I metabotropic glutamate receptors and expression of neurotrophins by NSCs
We then sought to investigate whether cellular signaling via group I mGluRs had any effect on the expression of mRNAs encoding for some of the most popular NSCassociated neurotrophic factors that include leukemia inhibitory factor (LIF), brain-derived neurotrophic factor (BDNF), and vascular endothelial growth factor (VEGF) [16] [17] [5] . To this aim, we optimized our experiments with SC-NSCs in glutamate-free tissue culture media containing small amounts (≥ 0.5 mM) of glutamine (control), or in control media added with 50 μM glutamate or 100 μM DHPG in combination with the different mGluRs antagonists. Glutamate and DHPG both led to a slight down-regulation of Vegf (Fig. 1F) , whereas the addition of LY367385 resulted in a further reduction. DHPG instead induced a significant up-regulation of the expression levels of Lif and Bdnf, which returned to control levels upon treatment with MPEP or LY367385 (Fig. 1F) . To determine the specificity of group I mGluR signaling in regulating Lif and Bdnf expression, we also investigated the effects of AMPA and NMDA receptor activation on SC-NSCs. Neither AMPA nor NMDA were able to induce a significant variation in the expression of Vegf, Lif or Bdnf, compared to controls (Fig. 1F) . Furthermore, AP5 and CNQX did not affect the expression of Vegf, Lif or Bdnf, neither in the presence of glutamate or DHPG, which altogether confirmed the specificity of the signaling through mGluR1 and mGluR5. We did observe an unexpected effect of LY367385 in the regulation of Vegf and Bdnf upon treatment with AMPA or NMDA, which might be attributable to some unknown interactions between mGluRs and iGluRs. We then verified whether an augmented protein secretion into tissue culture supernatants by ELISA paralleled the observed increase in gene expression. The secretion of LIF and BDNF increased similarly to correspondent mRNAs when SC-NSCs were treated with DHPG (Fig. 1G) , controls. LIF and BDNF levels slightly decreased also upon treatment with AP5 or CNQX (Fig. 1G) , as compared to mRNA expression (Fig. 1G) . The decrease in protein secretion was more pronounced when cells were treated with MPEP or LY367385. In particular, we observed that the presence of MPEP led to a greater decrease in BDNF expression, while LY367385 led to a more significant reduction of LIF. Here, we show that SC-NSCs express several components of the mGluRs family [15] 2+ is attributable to the action of group I mGluRs (mGlur1 and mGluR5). The activation of group I mGluRs, but not of NMDA or AMPA-associated receptors, led to an increase in the expression of LIF and BDNF, both in terms of mRNA and protein.
Altogether, these results suggest a novel pathway through which endogenous and transplanted SC-NSCs might exert neuroprotective effects observed in different pre-clinical studies. The increased extracellular concentration of glutamate as a consequence of cellular damage might contribute to promoting protective effects in recruited or transplanted NSCs.
Conclusions
Our work suggests a novel role for group I mGluRs in the regulation of Ca 2+ dynamics as well as LIF and BDNF expression in SC-derived NSCs. The release of neuroprotective factors has been shown to play a major role in the therapeutic potential of stem cells. These observations may, therefore, suggest the manipulation of group I mGluRs activity as a novel therapeutic approach. Once validated in the appropriate context, stem cell licensing/priming via mGluRs might represent a new strategy to foster the intrinsic neuroprotective capacities of both endogenous and transplanted NSCs.
Limitations
We reveal here a possible relation between the activation of group I mGluRs and the release of neurotrophic factors. This is an in vitro proof-of-concept study that deserves further confirmation both in vitro, e.g., by analyzing the intracellular signaling pathways regulating the described cellular responses, as well as in vivo in different contexts that include transplantation research and studies of neurogenic responses in health and disease.
The growth of SC-NSCs with media enriched of group I mGluR agonists (such as DHPG) or the genetic overexpression of mGluR1 and/or mGlur5 in NSCs may represent a valid approach to increase stem cells therapeutic efficacy in transplantation studies. 
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